Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03665129
Title IPH5401 (Anti-C5aR) in Combination With Durvalumab in Patients With Advanced Solid Tumors (STELLAR-001)
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements Yes
Sponsors Innate Pharma
Indications

lung non-small cell carcinoma

Advanced Solid Tumor

hepatocellular carcinoma

Therapies

Durvalumab + IPH5401

Age Groups: adult | senior
Covered Countries USA

Additional content available in CKB BOOST